SNGX : Summary for Soligenix, Inc. - Yahoo Finance

U.S. Markets closed

Soligenix, Inc. (SNGX)


OTC BB - OTC BB Real Time Price. Currency in USD
Add to watchlist
3.08-0.24 (-7.23%)
At close: 4:00PM EDT
People also watch
CBLIIDXGHTGMFCSCIMNP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.32
Open3.50
Bid2.93 x 200
Ask0.00 x
Day's Range2.87 - 3.50
52 Week Range1.90 - 9.00
Volume335,966
Avg. Volume602,901
Market Cap16.86M
Beta0.10
PE Ratio (TTM)-2.31
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Accesswire9 days ago

    Today's Research Reports on Biotech Stocks to Watch: Soligenix and MannKind

    NEW YORK, NY / ACCESSWIRE / April 20, 2017 / The Biotech Industry has outperformed the overall market, this year so far. This comes as a welcome sign to biotech investors after a tumultuous 2016. The iShares ...

  • PR Newswire10 days ago

    Efficacy Results from Soligenix's Ricin Toxin Vaccine Program to be Presented at the 20th Annual Conference on Vaccine Research

    PRINCETON, N.J., April 19, 2017 /PRNewswire/-- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that results from its ricin toxin vaccine (RiVax™) development program will be presented at the 20th Annual Conference on Vaccine Research, being held April 24-26 in Bethesda, Md. "Serum Antibody Profiling following Vaccination Reveals a Correlate of Immunity to Ricin Toxin" will be presented by Jennifer Yates, Ph.D., New York State Department of Health, Wadsworth Center and attended by Oreola Donini, Ph.D., Chief Scientific Officer of Soligenix, on April 25 at 2:15 p.m. Eastern time. RiVax™ is the Company's proprietary vaccine candidate for the prevention of exposure to ricin toxin that utilizes a unique antigen that is completely devoid of the toxic activity of ricin.

  • PR Newswire17 days ago

    Soligenix to Present at the World Orphan Drug Congress

    PRINCETON, N.J., April 12, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Ms. Karen Krumeich, Senior Vice President and Chief Financial Officer, will present a company overview entitled, "Rare Disease Treatment in Cutaneous T-cell Lymphoma and Oral Mucositis" at the World Orphan Drug Congress USA on Friday, April 21, 2017 at 3:30 p.m. Eastern time. The event will take place April 19-21, 2017 at the Washington Marriott Wardman Park in Washington, DC.